Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 27, 2018 08:00 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets

HAYWARD, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (“Anthera” or the “Company”) announced today that it has withdrawn its request for a hearing to appeal...
March 12, 2018 08:00 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura

Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”)Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”)Further development...
March 07, 2018 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference

HAYWARD, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and...
March 06, 2018 14:45 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria

HAYWARD, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that Anthera has received formal notice from The NASDAQ Stock Market LLC (“Nasdaq”)...
March 05, 2018 16:05 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results

RESULT study reported positive interim futility analyses and completion of dosing, with top line data expected in March 2018Completed private placement for net proceeds of $13.3 million...
February 08, 2018 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orphan Drug Day

HAYWARD, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and...
February 05, 2018 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura

HAYWARD, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) is pleased to announce that the final patient has completed the last visit in the primary treatment...
January 25, 2018 16:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Receives Positive Nasdaq Listing Determination

HAYWARD, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that on January 24, 2018, Anthera received formal notice that the Nasdaq Hearings Panel...
January 22, 2018 08:30 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter

HAYWARD, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced a positive outcome of the second, pre-specified interim futility analysis for the...
January 09, 2018 17:15 ET | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering

HAYWARD, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has completed the second closing of the private placement of its equity...

Next Page keyboard_arrow_right